In pre-clinical models, they have tested human iNKT cells purified with the iNKTCR mAb 6B11 for their ability to express GD2 CARs (against neuroblastomas) and CD19 CARs (against B cell lymphomas) (73, 74). Here, CD19 is linked to neuroblastoma.